Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 2(64), 2020
DOI: 10.1128/aac.02165-19
Links
Tools
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants
Journal article published in 2019 by
Pablo A. Fraile-Ribot,
Ester del Barrio-Tofiño,
Pedro de la Iglesia,
Nelly Daniela Zurita,
Irina Sánchez-Diener,
Carla López-Causapé,
Fraile Ribot Pa,
Laura Zamorano,
Antonio Oliver 
,
Rocío Orellana,
Manuel Antonio Rodríguez,
Lina Martín,
Juan Manuel Sánchez,
Laura Viñuela,
José Antonio Lepe
and other authors.
,
Rocío Orellana,
Manuel Antonio Rodríguez,
Lina Martín,
Juan Manuel Sánchez,
Laura Viñuela,
José Antonio Lepe
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%).